Why Axsome Therapeutics, Inc. (AXSM) stock moved
Axsome Therapeutics, Inc. (AXSM) shares tumbled 5.8% to $204.07 as of September 16, 2026, a significant decline from the prior close of $216.58. BestStocks flagged the session as a major change for AXSM. The move is tied to price move down. Below, we break down what changed for AXSM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
AXSM fell 5.8% to $204.07
Axsome Therapeutics fell 4.7% on August 20, 2026, as investors digested the company's Q2 earnings report, which revealed a net loss of $51.3 million despite strong revenue growth of $218.4 million driven by its flagship product Auvelity. The decline reflects concern over elevated operating expenses tied to commercialization efforts and delayed near-term profitability, compounded by broader risk-off sentiment in mid-cap biotech equities amid a high-interest-rate environment.
What it means for Axsome Therapeutics, Inc. investors
For Axsome Therapeutics, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Positive price momentum; Axsome Therapeutics, Inc. (AXSM) moved +6.91% from $221.64 to $236.95 on 2026-07-21. Weighing against that: Material negative event; Sharp 5.8% decline — elevated risk. Wall Street's consensus price target sits at $282.53, implying +38.4% upside from $204.07. BestStocks rates the overall signal quality low (56/100). With earnings roughly 47 days out, the next report is the most likely near-term test of the move.
AXSM price reaction
AXSM last traded at $204.07, down $12.51 (-5.78%) from the previous close of $216.58. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $198.52 and $220.75, and it currently sits about 25% of the way up that band.
Bullish and bearish analyst opinions on Axsome Therapeutics, Inc. (AXSM)
The consensus analyst price target on Axsome Therapeutics, Inc. (AXSM) is $282.53, 38.4% above the recent $204.07. Over the past 90 days analysts logged 0 upgrades, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on AXSM line up.
The bullish case
- Wall Street's consensus price target of $282.53 implies +38.4% upside from $204.07.
- The Street's most bullish target is $380.00 (+86.2%).
- Positive price momentum.
- Axsome Therapeutics, Inc. (AXSM) moved +6.91% from $221.64 to $236.95 on 2026-07-21.
The bearish case
- Material negative event.
- Sharp 5.8% decline — elevated risk.
- Axsome Therapeutics, Inc. (AXSM) moved -2.97% from $237.04 to $230.00 on 2026-07-17.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 16, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for AXSM
In-depth AXSM event analyses
Frequently asked questions about AXSM
Why did Axsome Therapeutics, Inc. (AXSM) stock move?
Axsome Therapeutics fell 4.7% on August 20, 2026, as investors digested the company's Q2 earnings report, which revealed a net loss of $51.3 million despite strong revenue growth of $218.4 million driven by its flagship product Auvelity. The decline reflects concern over elevated operating expenses tied to commercialization efforts and delayed near-term profitability, compounded by broader risk-off sentiment in mid-cap biotech equities amid a high-interest-rate environment.
How much did AXSM stock fall?
AXSM lost 5.78% ($12.51) versus the prior close of $216.58, last trading at $204.07 on 0.7× average volume.
When is Axsome Therapeutics, Inc.'s next earnings date?
AXSM's next earnings report is estimated for 2026-11-02 — about 47 days away.
What is the analyst price target for AXSM?
The consensus analyst price target for AXSM is $282.53, about 38.4% above the current $204.07. Over the past 90 days, analysts recorded 0 upgrades, 11 maintains, and 0 downgrades.
How BestStocks tracks AXSM
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for AXSM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 16, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.